Clinical Trial Evaluating the Safety of the TQB2103 for Injection
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
TQB2103 injection is an antibody-drug conjugate (ADC) targeting claudin (CLDN) 18.2. This
study aimed to evaluate the safety and tolerability, pharmacokinetic characteristics and
immunogenicity of TQB2103 injection in patients with advanced malignant tumors as well as its
initial effectiveness.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.